AVTR Stock Analysis: Avantor | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 6.848m USD | 12M Return: -26.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 85.9M
Qual. Beats: 0
Rev. Trend: -98.0%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.1 years of data
Average return per month, with how dependable it is below — did the month move the same way every year (high) or randomly (low). Above 60 is a pattern worth trusting; under 40 is noise.
Avantor, Inc. is a global supplier of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries, with operations across the Americas, Europe, Asia, the Middle East, and Africa. Its offering spans three main areas: materials and consumables (including purity chemicals, reagents, lab supplies, customized excipients, single-use assemblies, and chromatography resins), equipment and instrumentation (such as filtration systems, incubators, analytical instruments, and ultra-low-temperature freezers), and a broad services portfolio covering onsite lab and production support, procurement and sourcing, biopharmaceutical material scale-up, and scientific research support like DNA extraction and bioreactor servicing.
The company operates as a B2B distribution and value-added supply partner embedded in the life sciences workflow, supplying the inputs, tools, and outsourced services that biopharma and research customers use to develop and manufacture products rather than developing proprietary therapeutics itself. Founded in 1904 and headquartered in Radnor, Pennsylvania, Avantor has been publicly traded since its May 2019 IPO and is classified in the GICS Health Care sector under the Life Sciences Tools & Services sub-industry.
- Bioproduction demand recovery drives lab products revenue growth
- Raw material inflation pressures gross margins amid pricing actions
- Masterflex BioPharma acquisition expands single-use bioprocessing capabilities
| Net Income: -551.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.64 > 1.0 |
| NWC/Revenue: 15.83% < 20% (prev 3.71%; Δ 12.12% < -1%) |
| CFO/TA 0.05 > 3% & CFO 573.2m > Net Income -551.4m |
| Net Debt (3.54b) to EBITDA (126.9m): 27.87 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (679.3m) vs 12m ago -0.45% < -2% |
| Gross Margin: 32.13% > 18% (prev 33.56%; Δ -1.43% > 0.5%) |
| Asset Turnover: 54.63% > 50% (prev 54.23%; Δ 0.39% > 0%) |
| Interest Coverage Ratio: -1.58 > 6 (EBIT TTM -288.6m / Interest Expense TTM 182.9m) |
| A: 0.09 (Total Current Assets 2.40b - Total Current Liabilities 1.37b) / Total Assets 11.7b |
| B: 0.15 (Retained Earnings 1.72b / Total Assets 11.7b) |
| C: -0.02 (EBIT TTM -288.6m / Avg Total Assets 12.0b) |
| D: 0.92 (Book Value of Equity 5.59b / Total Liabilities 6.07b) |
| Altman-Z'' = 1.87 = BBB |
| DSRI: 1.03 (Receivables 1.10b/1.10b, Revenue 6.55b/6.69b) |
| GMI: 1.04 (GM 33.56% / 32.13%) |
| AQI: 0.96 (AQ_t 0.73 / AQ_t-1 0.76) |
| SGI: 0.98 (Revenue 6.55b / 6.69b) |
| TATA: -0.10 (NI -551.4m - CFO 573.2m) / TA 11.7b) |
| Beneish M = -3.01 (Cap -4..+1) = AA |
As of July 01, 2026, the stock is trading at USD 9.90 with a total of 5,240,383 shares traded. Over the past week, the price has changed by +4.98%, over one month by +7.73%, over three months by +26.28% and over the past year by -26.45%.
Current recommended Stop Loss: 9.40 (which is 5.1% or 1.2 ATR below the current price).
Avantor has received a consensus analysts rating of 3.76. Therefore, it is recommended to hold AVTR.
- StrongBuy: 6
- Buy: 4
- Hold: 11
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9.8 | -1.2% |
P/E Forward = 12.7714
P/S = 1.0452
P/B = 1.2253
Revenue TTM = 6.55b USD
EBIT TTM = -288.6m USD
EBITDA TTM = 126.9m USD
Long Term Debt = 3.78b USD (from longTermDebt, last quarter)
Short Term Debt = 37.0m USD (from shortTermDebt, last quarter)
Debt = 3.82b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.54b USD (calculated: Debt 3.82b - CCE 279.3m)
Enterprise Value = 10.4b USD (6.85b + Debt 3.82b - CCE 279.3m)
Interest Coverage Ratio = -1.58 (Ebit TTM -288.6m / Interest Expense TTM 182.9m)
EV/FCF = 23.66x (Enterprise Value 10.4b / FCF TTM 438.9m)
FCF Yield = 4.23% (FCF TTM 438.9m / Enterprise Value 10.4b)
FCF Margin = 6.70% (FCF TTM 438.9m / Revenue TTM 6.55b)
Net Margin = -8.42% (Net Income TTM -551.4m / Revenue TTM 6.55b)
Gross Margin = 32.13% ((Revenue TTM 6.55b - Cost of Revenue TTM 4.45b) / Revenue TTM)
Gross Margin QoQ = 31.66% (prev 31.49%)
Tobins Q-Ratio = 0.89 (Enterprise Value 10.4b / Total Assets 11.7b)
Interest Expense / Debt = 4.79% (Interest Expense 182.9m / Debt 3.82b)
Taxrate = 21.98% (12.2m / 55.5m)
NOPAT = -225.2m (EBIT -288.6m * (1 - 21.98%)) [loss with tax shield]
Current Ratio = 1.76 (Total Current Assets 2.40b / Total Current Liabilities 1.37b)
Debt / Equity = 0.68 (Debt 3.82b / totalStockholderEquity, last quarter 5.59b)
Debt / EBITDA = 27.87 (Net Debt 3.54b / EBITDA 126.9m)
Debt / FCF = 8.06 (Net Debt 3.54b / FCF TTM 438.9m)
Total Stockholder Equity = 5.75b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.60% (Net Income -551.4m / Total Assets 11.7b)
RoE = -9.59% (Net Income TTM -551.4m / Total Stockholder Equity 5.75b)
RoCE = -3.03% (EBIT -288.6m / Capital Employed (Equity 5.75b + L.T.Debt 3.78b))
RoIC = -2.24% (negative operating profit) (NOPAT -225.2m / Invested Capital 10.1b)
WACC = 6.80% (E(6.85b)/V(10.7b) * Re(8.51%) + D(3.82b)/V(10.7b) * Rd(4.79%) * (1-Tc(0.22)))
Discount Rate = 8.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -22.47 | Cagr: 0.01%
[DCF] Terminal Value 73.10% ; FCFF base≈529.9m ; Y1≈464.7m ; Y5≈375.4m
[DCF] Fair Price = 3.65 (EV 6.03b - Net Debt 3.54b = Equity 2.49b / Shares 682.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: -98.03 | Revenue CAGR: -3.12% | SUE: 2.06 | # QB: 2
EPS next Quarter (2026-09-30): EPS=0.20 | Chg30d=-0.29% | Revisions=-7% | Analysts=16
EPS current Year (2026-12-31): EPS=0.79 | Chg30d=+0.09% | Revisions=+0% | GrowthEPS=-12.3% | GrowthRev=-0.8%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-0.09% | Revisions=+7% | GrowthEPS=+7.8% | GrowthRev=+2.1%
[Analyst] Revisions Ratio: -7%